Key result
Early application of recombinant human brain natriuretic peptide protected renal function and decreased the incidence of contrast-induced nephropathy after primary PCI (P=0.017).
Why the study?
Whether recombinant human brain natriuretic peptide (rhBNP) can improve renal function and reduce contrast-induced nephropathy risk in elderly acute myocardial infarction patients was unclear.
Does recombinant human brain natriuretic peptide (rhBNP) improve renal function and decrease the risk of contrast-induced nephropathy in elderly acute myocardial infarction patients after PCI?
RCT
Does recombinant human brain natriuretic peptide (rhBNP) improve renal function and decrease the risk of contrast-induced nephropathy in elderly acute myocardial infarction patients after PCI?
Early application of recombinant human brain natriuretic peptide (rhBNP) may protect renal function and decrease the incidence of contrast-induced nephropathy in elderly AMI patients undergoing primary PCI.
Answers are grounded in this paper and cite their sources.
rhBNP reduced CIN incidence after PCI in elderly AMI; extends renal protection data and supports larger confirmatory trials.
BACKGROUND: Increasing reports have demonstrated that recombinant human brain natriuretic peptide (rhBNP) can improve acute myocardial infarction (AMI) and heart failure. However, whether it can improve renal function and decrease the risk of contrast-induced nephropathy (CIN) in elderly AMI patients is still unclear. AIM: To explore the effect of rhBNP on CIN in elderly AMI patients after percutaneous coronary intervention (PCI). METHODS: = 65). Serum creatinine and cystatin C levels, creatinine clearance rate, and eGFR were measured at 24 h, 48 h, and 72 h after PCI. Research nurses collected data on handwritten forms, and then stored them in password-protected electronic databases. No significant difference was noted between the two groups in cardiac death and recurrent AMI. CONCLUSION: Early application of rhBNP could protect renal function and decrease the incidence of CIN after primary PCI and acute heart failure.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2022) conducted an RCT in Acute myocardial infarction. Recombinant human brain natriuretic peptide (rhBNP) vs. Control was evaluated on Contrast-induced nephropathy and renal function (serum creatinine, cystatin C, creatinine clearance, eGFR) (p=0.017). Early application of recombinant human brain natriuretic peptide protected renal function and decreased the incidence of contrast-induced nephropathy after primary PCI (P=0.017).
Synapse has enriched 10 related papers. Consider them for comparative context: